KUALA LUMPUR (Feb 10): TMC Life Sciences Bhd (KL:TMCLIFE) has named Datuk Adzuan Abdul Rahman as the group’s new chief executive officer (CEO) effective immediately.

Melvin Heng Jun Li, who has been acting as the CEO, is redesignated as non-independent non-executive director, according to a bourse filing on Monday. Adzuan, trained as a doctor, will also assume the role of regional senior director at Singapore-listed parent Thomson Medical Group Ltd.

Adzuan brings along expertise in hospital operations, corporate strategy and organisational growth, TMC Life said, citing his various leadership tenures at private hospitals.

His experience as a medical practitioner, combined with his leadership in hospital management and the broader healthcare industry, “uniquely positions him to drive TMC Life Sciences’ growth and transformation,” said Heng, who is also the CEO of Thomson Medical Group.

“His strategic vision and ability to forge strong partnerships will be pivotal in further positioning TMC Life as a key player in the region’s healthcare landscape, enabling us to deliver greater value to both patients and stakeholders,” he added.

Adzuan’s appointment as TMC Life Sciences’ group CEO follows dismissal of predecessor Wan Nadiah Wan Abdullah Yaakob in December 2024 over alleged misconduct in the since-terminated contracts with two insurers, as well as the entry into an agreement with T-Systems Malaysia Sdn Bhd.

Wan Nadiah was dismissed following a domestic inquiry into the misconduct allegations, which concluded with a guilty verdict. She had been suspended from her roles in the group since January that year, and had said she intended to appeal the decision.

Thomson Medical Group owns a 70.13% stake in TMC Life Sciences.

At noon break on Monday, shares in TMC Life Sciences were unchanged at 47 sen, valuing the group at RM810.33 million.

Read also:
Wan Nadiah says she will appeal following her dismissal as TMC Life Sciences CEO
TMC Life Sciences CEO Wan Nadiah found guilty of misconduct after domestic inquiry